Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

NDA submission for Aczone

Sep. 3, 2004

Good efficacy and safety profile found for XP-828L in mild to moderate psoriasis

Sep. 3, 2004

Ark signs marketing agreement with Teva for Keraboot in Israel

Sep. 1, 2004

Preliminary phase II results for XMP-629

Aug. 19, 2004

Novel allosteric modulators of muscarinic receptors for psoriasis and other disorders

Aug. 19, 2004

Zimycan meets endpoints in phase III study for Candida diaper dermatitis

Aug. 16, 2004

New aminobenzophenone prodrugs and their use in skin inflammatory disorders

Aug. 16, 2004

Sculptra receives FDA approval for lipoatrophy

Aug. 9, 2004

Novel small molecule immunomodulating agent for eczema/psoriasis therapy

Aug. 5, 2004

TRX4 evaluated in new phase I study for psoriasis

Aug. 5, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.